Search Results
9 results found-
Patients were randomized 3:2 to receive a loading dose of 400 mg followed by 200 mg of ANDEMBRY monthly (n=39) or volume matched placebo monthly (n=25) subcutaneously.
https://newsroom.csl.com/2025-06-16-U-S-Food-and-Drug-Administration-Approves-CSLs-ANDEMBRY-R-garadacimab-gxii-,-the-Only-Prophylactic-Hereditary-Angioedema-HAE-Treatment-Targeting-Factor-XIIa-with-Once-Monthly-Dosing-for-All-Patients-From-the-Start -
A patient went looking for a way to explain life with a chronic illness and came up with a metaphor that stuck.
https://www.csl.com/we-are-csl/vita-original-stories/2020/living-with-chronic-illness-spoon-by-spoon -
TOVs solely related to over-the-counter medicines
https://www.csl.com/-/media/shared/documents/cslviforireland_method_2024.pdf -
ToVs solely related to over-the-counter medicines - ToVs excluded from the scope of the EFPIA Disclosure Code, such as informational and educational materials, items of medical utility, food and beverage, medical samples - Fees charged by logistics agencies assisting in organising travel and meetings
https://www.csl.com/-/media/shared/documents/vifor-disclosures/tov/2024_methodologicalnote_switzerland_draft.pdf -
ToVs solely related to over-the-counter medicines - ToVs excluded from the scope of the EFPIA Disclosure Code, such as informational and educational materials, items of medical utility, food and beverage, medical samples - Fees charged by logistics agencies assisting in organising travel and meetings
https://www.csl.com/-/media/shared/documents/vifor-disclosures/tov/2023_methodologicalnote_switzerland_20240626.pdf -
TOVs solely related to over-the-counter medicines
https://www.csl.com/-/media/shared/documents/vifor-disclosures/methodological-notes/cslviforireland_method_2023_.pdf -
A doctor, two patients and an organizational expert share tips for managing multiple prescriptions.
https://www.csl.com/we-are-csl/vita-original-stories/2023/organizing-medicines -
It is a global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating the safety and efficacy of 400 mg of sparsentan, compared to 300 mg of irbesartan, in 404 patients ages 18 years and up with IgAN and persistent proteinuria despite receiving maximum tolerated dose and at least 50% of maximum labelled dose of ACE or ARB therapy.
https://newsroom.csl.com/2024-02-23-CSL-Vifor-and-Travere-Therapeutics-announce-sparsentan-receives-positive-CHMP-opinion-for-the-treatment-of-IgA-nephropathy -
ToVs solely related to over-the-counter medicines - ToVs excluded from the scope of the EFPIA Disclosure Code, such as informational and educational materials, items of medical utility, food and beverage, medical samples - Fees charged by logistics agencies assisting in organising travel and meetings
https://www.csl.com/-/media/shared/documents/vifor-disclosures/methodological-notes/methodological-note_2022_ch.pdf